I wonder if there is another option - the outright sale (licensing?) of Trofinetide.
I don't see that as viable, for reasons I've stated before i.e. because that would leave a cashed up NEU with 2591 to develop (or as I think of it: Trofinetide 2.0). But this is another option that I don't see listed in your message above Baldwix, and it is a possibility.
- Forums
- ASX - By Stock
- NEU
- Possible outcomes?
NEU
neuren pharmaceuticals limited
Add to My Watchlist
2.00%
!
$16.66
Possible outcomes?, page-6
-
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
